Please login to the form below

Not currently logged in

Novartis licenses tuberculosis R&D to TB Alliance

Includes drugs to tackle resistant forms of the disease
Novartis building

Pharma company Novartis is to transfer its entire R&D programme for tuberculosis to not-for-profit research group the Global Alliance for TB Drug Development (TB Aliiance).

As part of the deal the TB Alliance will assume financial and operational responsibility for the continued research into potential TB treatments discovered at the Novartis Institutes for Tropical Diseases (NITD).

This pipeline includes a novel class of drugs called indolcarboxamides that are active against drug sensitive and multi-resistant strains of TB.

Resistance to current TB treatments is a major public health issue in developing nations and the World Health Organization (WHO) said last year that an extra $1.3bn needs to be raised each annually until 2016 to address the issue.

Specific compounds highlighted by Novartis include NITD304, which blocks the protein MmpL3 - an essential component for the survival of TB bacterium.

Novartis said it chose the TB Alliance to develop its TB pipeline as the organisation “has the best combination of expertise, capacity, and strategic interest to develop new agents and regimens for TB”.

Mark Fishman, president of Novartis Institutes for BioMedical Research, said: "TB Alliance is well placed to take our discoveries and compounds through development for the benefit of patients with TB."

The decision was also helped by the fact that the two organisations have collaborated in the past.

“Our long-standing partnership with Novartis gives us confidence in the scientific underpinnings of the TB portfolio,” said Dr Mel Spigelman, president and CEO of TB Alliance.

“We look forward to advancing the most promising compounds into the clinic to meet the urgent need for new TB treatments.”

The TB Alliance also has partnerships with other pharma companies including Sanofi.

20th August 2014

From: Research, Healthcare



COVID-19 Updates and Daily News

Featured jobs


Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...